Literature DB >> 9749638

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

A M Atta1, J Correa, M L Atta, R P Almeida, E M Carvalho.   

Abstract

Visceral leishmaniasis (VL) is characterized by a depression of the T helper cell type 1 immune response. Although mRNA expression for interleukin-4 (IL-4) is observed, evidence of the role of this cytokine in the pathogenesis of VL has been lacking. Since IL-4 is involved in IgE synthesis, we measured the total IgE and Leishmania antigen-specific IgE antibody levels in sera from patients with VL. Specific IgE antibodies detected by an ELISA technique after absorbing the sera with purified sheep IgG anti-human IgG were found in all 23 patients with VL and were not detected in subjects with subclinical Leishmania chagasi infection (n = 10), Chagas' disease (n = 10), atopic patients (n = 10), and healthy controls (n = 10). Levels of Leishmania-specific IgE (optical density values) before and after treatment were 0.100 +/- 0.03 (mean +/- SD) and 0.028 +/- 0.002, respectively (P < 0.05). These results indicate that a specific IgE response is useful in the diagnosis of active disease and to evaluate response to treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749638     DOI: 10.4269/ajtmh.1998.59.426

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  9-O-acetylated sialoglycoproteins are important immunomodulators in Indian visceral leishmaniasis.

Authors:  Angana Ghoshal; Sumi Mukhopadhyay; Bibhuti Saha; Chitra Mandal
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

4.  Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis.

Authors:  V L da Matta; S Hoshino-Shimizu; R Dietze; C E Corbett
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

5.  Association between atopy and recurrent vaginal candidiasis.

Authors:  N A Neves; L P Carvalho; M A M De Oliveira; P C Giraldo; O Bacellar; A A Cruz; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  Immunoglobulin E antileishmanial antibody response in cutaneous leishmaniasis.

Authors:  Maria L B Sousa-Atta; Gregório S Salamé; Argemiro D'Oliveira; Roque P Almeida; Ajax M Atta; Edgar M Carvalho
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

7.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.

Authors:  Rajesh Ravindran; Khairul Anam; Bibhas C Bairagi; Bibhuti Saha; Netai Pramanik; Subhasis K Guha; Rama P Goswami; Dwijadas Banerjee; Nahid Ali
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Comparative immune study on cutaneous leishmaniasis patients with single and multiple sores.

Authors:  Ban Noori Al-Qadhi; Israa Salim Musa; Yassir Mustafa Kamal Al-Mulla Hummadi
Journal:  J Parasit Dis       Date:  2013-11-21

10.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.